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Abstract
3, 4, 4’- Trichlorocarbanilide (triclocarban, TCC) is widely used as an antimicrobial agent in a
variety of consumer and personal care products. TCC is considered a potential endocrine
disruptor, but its potential toxic effects in humans are still largely unknown. Because of its
widespread uses, the potential for human exposure to TCC is high. In order to identify adequate
exposure biomarkers of TCC, we investigated the metabolic profile of TCC in adult female
Sprague Dawley rats after administering TCC once (500 mg/kg body weight) by oral gavage.
Urine was collected 0–24 hours before dosing, and 0–24 hours and 24–48 hours after dosing.
Serum was collected at necropsy 48 h after dosing. We identified several metabolites of TCC in
urine and serum by on-line solid phase extraction-high performance liquid chromatography- mass
spectrometry. We unambiguously identified two major oxidative metabolites of TCC, 3’-hydroxy-
TCC and 2’-hydroxy-TCC, by comparing their chromatographic behavior and mass spectral
fragmentation patterns with those of authentic standards. By contrast, compared to these oxidative
metabolites, we detected very low levels of TCC in the urine or serum. Taken together these data
suggest that in rats, oxidation of TCC is a major metabolic pathway. We also measured TCC and
its oxidative metabolites in 50 urine and 16 serum samples collected from adults in the United
States. The results suggest differences in the metabolic profile of TCC in rats and in humans;
oxidation appears to be a minor metabolic pathway in humans. Total (free plus conjugated) TCC
could serve as a potential biomarker for human exposure to TCC.
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1. Introduction
3, 4, 4’- Trichlorocarbanilide (TCC) is widely employed as an antimicrobial agent in a
variety of consumer and personal care products including bar soap, detergents, toothpaste,
deodorant, and cleansing lotions (The Personal Care Products Council 2011). With an
annual production and/or import volume in the United States of at least half a million
pounds, TCC is classified as a high production volume chemical requiring environmental
risk assessment by the U.S. Environmental Protection Agency (EPA 2002). TCC may persist
in water even after wastewater treatment (Heidler et al. 2006). As a result, TCC has been
detected in surface waters, municipal waste water treatment effluents, estuarine sediments,
and in streams nationwide (Halden and Paull 2005; Heidler and Halden 2009; Miller et al.
2008; Sapkota et al. 2007; Young et al. 2008).
Some toxicologic studies suggested that TCC could impair mammalian reproduction by
reducing birth weight and survival rate in rats (Nolen and Dierckman 1979). In humans,
exposure to TCC has been associated with methemoglobinemia (Johnson et al. 1963). TCC
is considered an endocrine disruptor even though TCC does not compete with some
endogenous hormones for receptor binding, but at high concentrations could enhance
estradiol (E2)-dependent or testosterone (T)-dependent activation of ER- and AR-responsive
gene expression in cell-based assays and in rats (Ahn et al. 2008; Chen et al. 2008).
Although the potential adverse health effects of TCC in humans are still largely unknown,
human exposure to TCC is known to occur and ongoing in the general population because of
the widespread use of this compound. Therefore, a need exists to identify adequate exposure
biomarkers of TCC. For this purpose, understanding the metabolic fate of TCC is necessary.
Dermal exposure is believed to be the main route of human exposure to TCC because TCC
is largely used in some personal care products (EPA 2002). Of interest, early publications on
the metabolism of TCC in rats suggested that after oral, intravenous, or dermal
administration of 14C-TCC, TCC was mainly excreted in bile and feces (Hiles 1977; Howes
and Black 1976; Warren et al. 1978), regardless of the route of administration (Warren et al.
1978). Less than 6% of the administered dose was excreted in urine (Warren et al. 1978).
The major biliary and fecal metabolites were identified as nonconjugated and conjugated
TCC and 2’-hyhroxy-TCC (2’-OH-TCC) (Jeffcoat et al. 1977; Warren et al. 1978). Other
research in monkeys and humans following oral or intravenous administration of TCC also
suggested that TCC and its metabolites were mainly excreted in bile (Birch et al. 1978; Hiles
et al. 1978; Hiles and Birch 1978; Scharpf et al. 1975). Unfortunately, bile and feces are not
the most adequate matrices for biomonitoring purposes primarily because of collection-
related issues. By contrast, validated protocols for the collection of blood and urine for
biomonitoring purposes do exist.
The main objective of the present study was to identify metabolites of TCC in the urine and
serum of adult female Sprague Dawley rats administered with TCC. We also evaluated the
usefulness of these TCC urinary and serum metabolites as biomarkers of TCC exposure in
humans by measuring these compounds in 50 urine and 16 serum specimens collected from
U.S. adults without known occupational exposure to TCC.
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2. Materials and methods
2.1 Animal Experiments
The animal treatment protocol was reviewed and approved by the EPA Internal Animal Care
and Use Committee. Twelve female Sprague-Dawley rats (Harlan Laboratories,
Indianapolis, IN) about 60 days of age were housed individually in clear polycarbonate
cages (20×25×47 cm) with laboratory grade pine shavings as bedding at the Reproductive
Toxicology animal facility of the U.S. Environmental Protection Agency (EPA) with a
12:12 light/dark cycle (lights off at 7:00 pm), temperature of 20–22°C and 45–55% relative
humidity, and provided with filtered (5 micron) water and NTP 2000 rat chow ad libitum.
After a 12-day acclimation period, rats were placed for four days in Fisher Nalgene Rodent
metabolism cages (Fisher catalogue # 01-287-6A) and given powdered feed and deionized/
filtered water via water bottles; three of the rats were used as controls. The first urine
samples (U0) were collected from all twelve rats on day 2, 0–24 hours after they were placed
in the metabolism cage. Then, we administered to nine of the rats 500 mg/kg body weight of
TCC with purity at 99 % (Sigma Aldrich Laboratories, Inc., St. Louis, MO, USA) in corn oil
by gavage. The second and third urine samples for both control (3 rats) and dosed (9 rats)
groups were collected on days 3 and 4, 0–24 hours (U1) and 24–48 hours (U2), respectively,
after TCC administration. After the third urine collection, the rats were euthanized by
exposure to excess CO2, and serum samples (S) were collected. The urine and serum
samples were placed in polypropylene vials and frozen at −70 °C until shipped on dry ice to
the Centers for Disease Control and Prevention’s National Center for Environmental Health
laboratory. On arrival, the samples were stored at −70 °C until analyzed.
2.2 Materials and Standards
HPLC-grade methanol was obtained from Tedia (Fairfield, OH) and analytical-grade formic
acid (98 %) was purchased from EM Science (Gibbstown, NJ). 4-methylumbelliferyl
glucuronide, 4-methylumbelliferyl sulfate, β-glucuronidase/sulfatase (Helix pomatia, H1),
and ammonium acetate (>98%) were purchased from Sigma Aldrich Laboratories, Inc. D7-
TCC and 13C4-4-methylumbelliferone were obtained from Cambridge Isotope Laboratories,
Inc (Andover, MA). 2’-OH-TCC and 3’-hyhroxy-TCC (3’-OH-TCC) were synthesized by
coupling the appropriate isocyanate and amine compounds as described previously (Ahn et
al. 2008; Warren et al. 1978).
2.3 Human Urine and Serum Specimens Collection
Fifty urine samples were collected anonymously in 2010 from a diverse group of male and
female adult volunteers in Atlanta, GA. A waiver of informed consent was requested under
45 CFR 46.116(d) and the Centers for Disease Control and Prevention Human Subjects
Institutional Review Board reviewed and approved the study protocol. No personal or
demographic data were available. Sixteen commercially available serum samples collected
between 1998 and 2003 from 5 male and 11 female donors were purchased from Tennessee
Blood Services (Memphis, TN). The potential exposure to TCC from any of the blood or
urine donors was unknown.
2.4 Analytical Method
For metabolite identification, 100 µL of rat urine were spiked with 50 µL of β-
glucuronidase/sulfatase (H. pomatia, 463 000U/g solid) in buffer solution at pH-5.0 (100 U)
and incubated at 37 °C for 4 h to hydrolyze the conjugates. The incubated samples were then
diluted to 1 mL with 0.1 M formic acid. TCC and its metabolites were extracted by the on-
line solid phase extraction (on-line SPE), separated using high performance liquid
chromatography (HPLC) and detected with mass spectrometry (MS). The on-line SPE-
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HPLC system used was similar to one described previously (Ye et al. 2008). Briefly, it
consisted of two binary pumps with degassers, an autosampler with a 900-µL injection loop,
and one column compartment with a 10-port switching valve (Agilent Technologies,
Wilmington, DE). The SPE column was a LiChrosphere RP-18 ADS (25 × 4 mm, 25 µm
particle size, 60 Å pore size, Merck KGaA, Germany), and the HPLC columns were two
Chromolith™ Performance RP-18 (100 × 4.6 mm; Merck KGaA). The mobile phases A and
B were water and 100 % MeOH, respectively, for both SPE and HPLC. TCC and its
metabolites were detected by negative electrospray ionization using an API 4000 Q Trap™
mass spectrometer (Applied Biosystems, Foster City, CA).
For the quantitative detection of total and free TCC and its metabolites in rat and human
urine (or serum), we used a modified on-line SPE-HPLC-MS/MS method (Ye et al. 2008)
similar to the one used for metabolite identification described above. We spiked urine or
serum (100 µL) with 50 µL of internal standard solution (D7-TCC), 50 µL of β-
glucuronidase/sulfatase (H. pomatia, 463 000U/g solid) in buffer (pH 5.0) (or 50 µL of pH 5
buffer without enzyme for free concentration measurements), and 50 µL of 0.5 ppm 4-
methylumbelliferyl glucuronide/4-methylumbelliferyl sulfate/13C4-4-methylumbelliferone
mixed standard. The 4-methylumbelliferone/13C4-4-methylumbelliferone peak area ratio
was monitored to evaluate the extent of the deconjugation reaction. Samples were incubated
for 4 hours at 37 °C, then acidified with 0.1 M formic acid (750 µL) before analysis by on-
line SPE-HPLC-MS/MS. We prepared analytical standards, quality control (QC) materials,
and blanks by using the same procedure as described above, except that we replaced the
urine/serum by the same volume of standard stock solution, QCs, or HPLC grade H2O (for
blanks). The limits of detection, calculated as 3S0 where S0 is the standard deviation as the
concentration approaches zero (Taylor 1987), were 0.1 ng/mL in both urine and serum for
all three analytes. The spiked recovery in urine or serum ranged from 83% to 120 % for the
three analytes at four spiking levels: 1, 2.5, 5, and 10 ng/mL.
3. Results and discussion
3.1 In vivo metabolism of TCC in rats
First, we obtained the full scan mass spectra of a TCC standard. The molecular ion and the
most abundant fragment ions were 313 ([M-H]−), 160 ([C6H4NCl]−), and 126
([C6H3NCl2]−). Under the experimental conditions described above, TCC eluted at 19.4
min. Because the metabolites of TCC could potentially fragment like the parent compound,
we obtained a precursor ion mass spectrum of m/z=160, the most abundant fragment ion of
TCC, from the rat urine samples (U1 and U2) after deconjugation and on- line SPE-HPLC
separation. We observed three major precursors: A (m/z = 313, retention time [RT] = 19.4
min), B (m/z = 345, RT = 18.3 min), and C (m/z = 329, RT = 17.9 min), but only in the
urine (U1 and U2) of the dosed rats (Figure 1A). We did not observe these three compounds
in any of the three control rats urine samples or in the urine collected before dosing (U0)
from the 9 dosed rats (data not shown).
Oxidized metabolites of TCC, such as 2’-OH-TCC, had been reported to be the major biliary
metabolites of TCC (Jeffcoat et al. 1977). Therefore, we also obtained the precursor ion
scans of the most abundant fragment ions for 2’-OH-TCC (m/z = 168) and 3’-OH-TCC (m/z
= 142) from urine collected from both dosed and control rats. We found a total of six
precursors of m/z 142 and m/z 168 only in the urine collected from dosed rats after
administering TCC (Figure 1B and 1C). These precursors were B, C, D (m/z = 329,
RT=19.2 min), E (m/z=345, RT=15.6 min), F (m/z-295, RT=16.1 min), and G (m/z-295,
RT=16.6 min) (Figure 1B and 1C).
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To identify these metabolites, we obtained the enhanced product ion (EPI) mass spectra of
the after-dose urine (U1) after on-line SPE-HPLC separation. By comparing with the EPI
data and retention times of the authentic standards, we unequivocally identified A as the
parent compound TCC (Figure 2A), D as the oxidized metabolite 2’- OH-TCC (Figure 2B),
and C as 3’-OH-TCC, another oxidized metabolite (Figure 2C). Metabolites B and E shared
the same molecular ion at m/z 345, but metabolite E eluted earlier (15.6 min) than
metabolite B (18.3 min). EPI scans of these two metabolites showed fragments at m/z 329,
160, 168 for metabolite B, and m/z 329, 142, 168 for metabolite E (data not shown). These
data suggested that metabolites B and E were dihydroxylated-TCC isomers, with the second
hydroxyl group on different sites of the ring. Similarly, we tentatively identified the two
other minor metabolites F and G (both with the same molecular ion m/z 295) as a pair of
dechlorinated hydroxy-TCC isomers. However, because of the lack of the authentic
standards, the structures of these two pairs of isomers could not be unequivocally
determined, and additional NMR experiments are needed to fully characterize the chemical
structures of these compounds.
We measured the total (free plus conjugated) and free concentrations of TCC and its two
metabolites, 2’-OH-TCC and 3’-OH-TCC, in rats urine and serum with multiple-reaction-
monitoring (MRM) after the target analytes were extracted and separated by the on-line
SPE-HPLC system. To increase the accuracy of the measurements, we added D7-TCC to the
samples as the internal standard for all of the three analytes. The ion transitions used for
quantitation (or confirmation) and the retention time of each target analyte are listed in
Table 1. Figure 3 shows the total and free median concentrations of TCC, 2’-OH-TCC, and
3’-OH-TCC from urine and serum samples collected from the 9 rats dosed with TCC on day
2 (pre-dose, U0), day 3 (U1), and day 4 (U2, S). We did not detect TCC or its metabolites in
the pre-dose urine (U0) samples (Figure 3). Similarly, we did not detect TCC or TCC
metabolites in any of the urine (U0, U1, and U2) and serum samples collected from three
control rats (data not shown). Within 24 hrs after dosing, TCC was rapidly metabolized to
the oxidative metabolites. 3’-OH-TCC appeared to be the main metabolite, with median
total urinary concentrations of 3210 ng/mL vs 102 ng/mL (2’-OH-TCC) and 16 ng/mL
(TCC) (Figure 3). The median urinary concentrations of 3’-OH-TCC after dosing dropped
about 15% from day 3 to day 4 to 2720 ng/mL, and urinary median concentration of 2’-OH-
TCC increased from 102 ng/mL to 900 ng/mL (Figure 3). We also detected 2’-OH-TCC and
3’-OH-TCC in serum, but at much lower levels than in the urine collected in the same after
administration; median serum concentrations were 55.1 ng/mL (2’-OH-TCC) and 33.4 ng/
mL (3’-OH-TCC). All of these findings suggest that TCC metabolized rapidly in rats
through phase I metabolism, and the major urinary metabolites of TCC were 3’-OH-TCC
and 2’-OH-TCC.
Furthermore, we detected 3’-OH-TCC mainly in its conjugated form; mean conjugate
percent (%), defined as the ratio of concentrations of conjugated and total species, was 88%
for urine collected in day 3 and 71% for urine collected in day 4. However, we detected
TCC and 2’-OH-TCC in urine primarily in their free form, and the mean conjugate ranged
from 14% to 25%. In serum, the main 3’-OH-TCC species was also its conjugate, with the
mean conjugate of 3’-OH-TCC at 95%, while the mean conjugate of TCC and 2’-OH-TCC
in serum were 1% and 65%, respectively.
Taken together, our data suggest that in the rat, after oral ingestion, TCC undergoes phase I
metabolism to form 3’- and 2’-OH-TCC, similar to di(2-ethylhexyl) phthalate in humans
(Koch et al. 2004; Koch et al. 2005). We speculate that most of 3’-OH-TCC was further
metabolized through phase II metabolism to its conjugate before urinary excretion. By
contrast, the formation and elimination of 2’-OH-TCC was slower than that of 3’-OH-TCC
and did not appear to involve extensive phase II metabolism. Unfortunately, we collected
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urine samples for only 48 hrs after dosing the animals. Therefore, we could not determine
whether additional amounts of 2’-OH-TCC conjugate would have excreted in urine more
than 2 days after dosing. Nonetheless, the study design was adequate to demonstrate that
TCC was rapidly metabolized through phase I and phase II metabolism, and that the
oxidative metabolites 3’-OH-TCC and 2’-OH-TCC were the major urinary metabolites of
TCC. Previous studies in rats (Hiles 1977; Howes and Black 1976; Warren et al. 1978),
monkeys, and humans (Birch et al. 1978; Hiles et al. 1978; Hiles and Birch 1978; Scharpf et
al. 1975) suggest similar metabolic pathways of TCC regardless of administration route
(e.g., oral, intravenous, dermal). Therefore, our results can be extrapolated to exposure
routes other than oral ingestion. However, additional research is needed to identify
unequivocally the metabolic profile of TCC by these other routes of exposure.
Of interest, our findings were also in agreement with a previous study which suggested that
2’-OH-TCC and 3’-OH-TCC were the main urinary oxidative metabolites based on the
percentage of the extracted radioactivity after repeated oral administration of TCC to three
rats (Warren et al. 1978). However, in that particular study, the majority of the urinary
radioactivity was recovered from the parent TCC, which did not happen in our study. We
speculate that these differences might be related to the much higher dose used in that study
(2000 ppm TCC in the diet for 10 days), which could potentially saturate the regular
metabolic pathway. Furthermore, our results are also in agreement with those from a recent
in vitro study suggesting that di-hydroxylated TCC and dechlorinated hydroxyl-TCC could
be formed by the oxidative metabolism of TCC (Baumann et al. 2010). However, we could
not confirm the formation of quinone imines in vivo, even though these compounds were
also suggested as potential oxidative metabolites of TCC in vitro (Baumann et al. 2010).
3.2 Measurements of TCC, 2’-OH-TCC and 3’-OH-TCC in human urine and serum
To check the usefulness of 2’-OH-TCC and 3’-OH-TCC, the major urinary metabolites of
TCC in rats, as biomarkers of human exposure to TCC for biomonitoring purposes, we
measured the total and free concentrations of TCC, 2’-OH-TCC and 3’-OH-TCC in 50 urine
samples collected anonymously in 2010 from adult volunteers in Atlanta, GA with no
documented occupational exposure to TCC (Table 2). We also measured the same
compounds in 16 commercial available serum samples collected between 1998 and 2003
from persons with no documented occupational exposure to TCC. In urine, we detected the
total species of TCC, 2’-OH-TCC and 3’-OH-TCC in up to a third of the samples; the
frequency of detection of TCC, 2’-OH-TCC and 3’-OH-TCC in urine ranged from 5.4% to
28% (Table 2). However, we detected TCC, not 3’-OH-TCC, at the highest frequency and
highest concentration ranges in urine. The administered dose (500 mg/kg body weight) was
relatively high and may have resulted in induction or inhibition of Phase I or Phase II
metabolic pathways. Nonetheless, our findings are consistent with a biotransformation study
conducted using rats, monkeys, and men which also suggested possible species differences
(human versus rat) in TCC metabolism (Birch et al. 1978). Furthermore, we found that the
conjugated forms of TCC, 3’-OH-TCC, 2’-OH-TCC were the main species in urine. Our
findings, albeit limited to a relatively small number of samples, are in agreement with early
research data in which people were orally dosed with TCC (Hiles and Birch 1978).
We did not detect 3’-OH-TCC and 2’-OH-TCC in any of the human serum samples, but we
detected TCC in about 50% of the serum examined, both in total and free forms. However,
TCC was detected in serum at a much lower level than in urine, with a mean concentration
at 0.45 ng/mL versus 3.85 ng/mL in urine. Like for other non- persistent compounds (e.g.,
phthalates, bisphenol A) to which humans are likely exposed through episodic—rather than
chronic—events, the concentrations in serum are much lower than the urinary
concentrations. This is the main reason why urine is the preferred biomonitoring matrix for
assessing exposure to non-persistent compounds (Needham and Sexton 2000). It is also
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important to note that the urine and serum results presented here are not from the same
individuals and collected years appart. Furthermore, the TCC serum results from these 16
samples must be interpreted with caution because TCC can be used in a variety of consumer
and personal care products, and we had no information on the procedures for collection,
processing, and storage of the samples analyzed. Therefore, we could not rule out the
possibility of contamination with the parent compound during the collection and processing
of the samples.
4. Conclusions
We investigated the metabolism of TCC in rats administered with a single oral dose of TCC.
We unambiguously identified two oxidative metabolites, 3’-OH-TCC and 2’-OH-TCC, as
the main urinary metabolites; we also detected the same metabolites in serum, but at much
lower concentrations than in urine. Interestingly, we detected TCC at higher frequency and
concentrations than those of its oxidative metabolites in 50 human urine samples, suggesting
that species differences in TCC’s metabolic profiles may exist. The total concentration of
TCC in urine was the most suitable biomarker for TCC exposure in humans. 2’-OH-TCC
and 3’-OH-TCC could be used to confirm TCC exposure in specific populations where
exposures may be higher than background levels or in situations of suspected contamination
of the urine specimen with TCC.
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• The metabolic profile of Triclocarban (TCC) in rats after oral administration of
TCC was investigated.
• We identified several metabolites of TCC in urine and serum collected from the
dosed rats.
• The usefulness of the identified metabolites of TCC as human biomarkers was
evaluated.
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Total ion chromatograms of precursor ion scans (m/z 160, 142, and 168) from urine samples
collected from nine rats after the administration of TCC.
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Enhanced product ion (EPI) mass spectra of different precursors in urine collected from rats
after the administration of TCC: A) precursor A, B) precursor D, and C) precursor C.
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Median total and free concentrations of TCC (A), 2’-OH-TCC (B), and 3’-OH-TCC (C)
from urine (U0, U1, and U2) and serum samples (S) collected from 9 rats dosed with 500
mg/kg body weight TCC. The error bars indicate the standard deviation of the
measurements.
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Table 1






TCC 19.4 313→160 (126)
2’-OH-TCC 19.2 329→168 (142)
3’-OH-TCC 17.9 329→168 (142)
a
For all of the analytes, we used D7-TCC as the internal standard and monitored the m/z ion transition 320→163.
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Table 2


































The limits of detections (LOD) of TCC, 2’-OH-TCC and 3’-OH-TCC were 0.1 ng/mL in urine.
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